A5020737978- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Palliative Care and End-of-Life Issues
- Biosimilars and Bioanalytical Methods
- Silicon Carbide Semiconductor Technologies
- CRISPR and Genetic Engineering
- T-cell and B-cell Immunology
- Safe Handling of Antineoplastic Drugs
- Cancer survivorship and care
- Polyomavirus and related diseases
- Neuroblastoma Research and Treatments
- Autoimmune and Inflammatory Disorders Research
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Renal Transplantation Outcomes and Treatments
- Advancements in Semiconductor Devices and Circuit Design
- Nanowire Synthesis and Applications
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
St. Jude Children's Research Hospital
2016-2025
University of Tennessee Health Science Center
2023
Children's Research Hospital
2022-2023
Max Delbrück Center
2023
The University of Texas Southwestern Medical Center
2023
Stanford University
2023
University of Michigan
2023
Thomas Jefferson University Hospital
2023
T cell-mediated hyperinflammatory responses, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), are now well-established toxicities of chimeric antigen receptor (CAR) cell therapy. As the field CAR cells advances, however, there is increasing recognition that hemophagocytic lymphohistiocytosis (HLH)-like following infusion occurring broadly across patient populations constructs. Importantly, these HLH-like often not directly associated with CRS...
Summary Chimeric antigen receptor T‐cell (CAR T‐cell) therapy is associated with significant toxicities secondary to immune activation, including a rare but increasingly recognised severe toxicity resembling haemophagocytic lymphohistiocytosis (carHLH). We report the development of carHLH in 14·8% paediatric patients and young adults treated CD19‐specific CAR carHLH, occurring most commonly those high disease burden. The diagnosis treatment required index suspicion included multidrug...
Current chimeric antigen receptor-modified (CAR) T-cell products are evaluated in bulk, without assessing functional heterogeneity. We therefore generated a comprehensive single-cell gene expression and receptor (TCR) sequencing data set using pre- postinfusion CD19-CAR T cells from blood bone marrow samples of pediatric patients with B-cell acute lymphoblastic leukemia. identified cytotoxic identical TCRs to subset preinfusion CAR cells. These effector precursor exhibited unique...
The treatment of pediatric high-risk neuroblastoma is intensive and multimodal. Despite the introduction immunotherapy for minimal residual disease, survival rates remain suboptimal new therapies are needed. As part a phase 2 trial, we using consolidation therapy regimen that combines busulfan/melphalan conditioning schema, autologous hematopoietic cell transplantation (AHCT), experimental with hu14.18K322A (a humanized anti-GD2 monoclonal antibody), granulocyte-macrophage colony-stimulating...
CD19-specific chimeric antigen receptor (CAR) T-cell therapies, including the FDA–approved tisagenlecleucel, induce high rates of remission in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, post-treatment relapse remains an issue. Optimal management B-ALL after tisagenlecleucel treatment elusive, and continued tracking outcomes is necessary to establish a standard care for this population. We sought evaluate on real-world use contemporary...
CD19-specific chimeric antigen receptor (CAR) T cell therapy has changed the treatment paradigm for pediatric, adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, data on associated infectious disease challenges in this patient population are scarce. Knowledge of infections presenting during treatment, risk factors, is critical pediatric cellular specialists as we seek to formulate effective anti-infective prophylaxis,...
Objectives: Lymphodepletion of host T-cells is thought to improve the ability CAR expand and persist. Recent studies have shown higher Fludarabine (FLU) cumulative systemic exposure was associated with lower risk relapse improved leukemia-free survival [1, 2] its pharmacokinetics (PK) are highly variable increased clearance in younger children [3]. We developed a model dynamics between lymphodepletion, T-cells, cytokines used simulations test hypotheses on how changes lymphodepletion...
Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL) effectively induce remission; however, disease recurrence remains a challenge. Due to the potential for antigen loss, diminution, lineage switch or development of secondary treatment-related malignancy, phenotype and manifestation subsequent may be elusive. We report on two patients with multiply relapsed/refractory B-ALL who, following chimeric receptor T-cell therapy, developed myeloid malignancies. In first...
Abstract Background Relapse remains a challenge after transplantation in pediatric patients with hematological malignancies. Myeloablative regimens used for disease control are associated acute and long-term adverse effects. We CD45RA-depleted haploidentical graft adoptive transfer of memory T cells combined NK-cell addback hypothesized that maximizing the graft-versus-leukemia (GVL) effect might allow reduction intensity conditioning regimen. Methods In this phase II clinical trial...